Table 1.
Demographics and baseline characteristics
| Patients | L.M.X.4 (n = 39) | Topicaine (n = 38) | Betacaine (n = 40) |
|---|---|---|---|
| Age (years), mean ± SD | 63 ± 13 | 62 ± 12 | 58 ± 11 |
| Male, % | 56 | 61 | 58 |
| Race, n (%) | |||
| White | 28 (72) | 28 (74) | 34 (85) |
| Black or African American | 5 (13) | 3 (8) | 2 (5) |
| Asian | 1 (3) | 0 | 0 |
| Other | 5 (13) | 7 (18) | 3 (8) |
| Neuropathic pain syndrome, n (%) | |||
| PDN | 30 (77) | 29 (76) | 32 (80) |
| PHN | 9 (23) | 8 (21) | 8 (20) |
| H IV-DSP | 0 | 1 (3) | 0 |
| Duration of pain (years), mean ± SD | 5.3 ± 5.55 | 4.5 ± 4.90 | 3.8 ± 3.91 |
| Baseline pain level, mean ± SD (range) | 5.6 ± 1.56 (2.5–8.2) | 5.9 ± 1.44 (3.5–8.4) | 5.4 ± 1.27 (3.0–7.8) |
| Baseline concomitant pain medication usea, n (%) | 24 (62) | 19 (50) | 23 (58) |
a
Note: A patient was defined as being on concomitant pain medication if he/she was on an anticonvulsant, non-SSRI antidepressant, or opioid that was used on day −1 and was taken for a total duration of at least 7 consecutive days.
Abbreviations: HIV-DSP, human immunodeficiency virus-associated distal sensory polyneuropathy; PDN, painful diabetic neuropathy; PHN, post-herpetic neuralgia; SD, standard deviation; SSRI, non-selective serotonin reuptake inhibitor.